Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Traitement par CEMP pour la Tendinopathie de l'Épaule

4 novembre 2026 mis à jour par: Elena-Valentina Ionescu, Balnear and Rehabilitation Sanatorium Techirghiol

<p>Effet de la thérapie par champ électromagnétique pulsé (CEMP) délivrée via le système super inductif (SIS) combinée à la balnéophysiothérapie chez les patients atteints de tendinopathies de l'épaule : un essai contrôlé randomisé</p>

The goal of this clinical trial is to evaluate whether pulsed electromagnetic field (PEMF) therapy delivered via the Super Inductive System (SIS), integrated into a multimodal rehabilitation program, improves pain, function, pressure pain threshold, muscle strength, psychological status, and quality of life in adults with shoulder tendinopathies.

The main questions it aims to answer are:

  • Does the addition of PEMF (SIS) therapy reduce pain intensity and improve pressure pain threshold compared to standard balneophysiotherapy?
  • Does PEMF (SIS) therapy improve shoulder function, muscle strength, psychological status, and quality of life? The study compares a multimodal rehabilitation program supplemented with PEMF (SIS) therapy to standard balneophysiotherapy to determine whether the addition of PEMF (SIS) provides superior clinical outcomes.

Participants will:

  • Undergo a multimodal rehabilitation program including balneophysiotherapy
  • Be assigned to receive either standard treatment or treatment supplemented with PEMF (SIS) therapy
  • Are assessed at four time points: T0 (baseline, at admission), T1 (immediately after completion of the 10-day treatment program), T2 (1 month after treatment completion), and T3 (3 months after treatment completion), using validated clinical instruments assessing pain, function, pressure pain threshold, muscle strength, psychological status, depressive symptoms, and quality of life.

Aperçu de l'étude

Description détaillée

Shoulder tendinopathies are a common cause of pain, functional limitation, and reduced quality of life, with a significant impact on daily activities. Their clinical presentation is heterogeneous, involving not only structural and functional impairments but also activity limitations and participation restrictions.

Conservative management remains the first-line approach and typically includes multimodal rehabilitation programs incorporating balneophysiotherapy, exercise therapy, and physical modalities. Although these interventions are widely used and have demonstrated clinical benefits, the optimal combination of therapeutic modalities remains a subject of ongoing research.

Pulsed electromagnetic field (PEMF) therapy delivered via the Super Inductive System (SIS) is a non-invasive intervention with potential analgesic, neuromodulatory, and regenerative effects. However, evidence regarding its additional benefit when integrated into standard multimodal rehabilitation programs for shoulder tendinopathies is still limited.

Given the multifactorial nature of shoulder tendinopathies, a multidimensional assessment approach is required. This study is based on the framework of the International Classification of Functioning, Disability and Health (ICF) and aligned with OMERACT recommendations, allowing a comprehensive evaluation of clinical outcomes across multiple domains.

The aim of this study is to compare the effectiveness of PEMF therapy delivered via SIS, integrated into a multimodal rehabilitation program, with standard balneophysiotherapy in patients with shoulder tendinopathies.

Participants are allocated to either a control group receiving standard treatment or an experimental group receiving the same rehabilitation program supplemented with PEMF (SIS) therapy. Clinical outcomes, including pain intensity, shoulder function, pressure pain threshold, muscle strength, psychological status, depressive symptoms, and quality of life, are assessed at four time points: T0 (baseline, at admission), T1 (immediately after completion of the 10-day treatment program), T2 (1 month after treatment completion), and T3 (3 months after treatment completion). The follow-up assessment aims to evaluate the maintenance of therapeutic effects over time.

This study seeks to determine whether the addition of PEMF (SIS) therapy provides superior outcomes within a multimodal rehabilitation strategy and supports a personalized, multidimensional approach to the management of shoulder tendinopathies.

Type d'étude

Interventionnel

Inscription (Réel)

83

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Techirghiol
      • Constanța, Techirghiol, Roumanie, 906100
        • Balneal and Rehabilitation Sanatorium of Techirghiol

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 70 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adults aged between 18 and 70 years.
  • Patients with chronic shoulder pain lasting more than 3 months, of non-traumatic origin, persistent despite prior conservative treatment.
  • Clinical diagnosis of shoulder tendinopathy and/or subacromial pain syndrome based on medical history and physical examination.
  • Presence of shoulder pain and functional limitation confirmed by clinical assessment and baseline functional evaluation (SPADI).
  • Ability to comply with the treatment protocol and attend scheduled follow-up assessments.
  • Provision of written informed consent prior to participation.

Exclusion Criteria:

  • Full-thickness rotator cuff tears with surgical indication.
  • Recent major shoulder trauma (within the last 6 months).
  • Active systemic inflammatory or rheumatologic diseases.
  • Presence of metallic implants in the treatment area or implanted electronic devices (e.g., pacemaker).
  • Neurological disorders affecting the upper limb.
  • Contraindications to balneotherapy (e.g., severe cardiovascular disease, renal failure, severe dermatological conditions).
  • Decompensated chronic diseases at the time of enrollment (cardiovascular, hepatic, renal, respiratory, or neurological).
  • Skin lesions at the site of treatment application.
  • Pregnancy or breastfeeding.
  • Active neoplastic disease.
  • Decompensated psychiatric disorders.
  • History of hypersensitivity to natural therapeutic factors used in balneotherapy.
  • Refusal to participate or inability to provide informed consent.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Balneophysiotherapy plus Nanopulsed Electromagnetic Field Therapy Group

Participants in the experimental group receive a standardized balneophysiotherapy program combined with nanopulsed electromagnetic field therapy (Super Inductive System) applied to the affected shoulder, delivered over 10 treatment days at the Balneal and Rehabilitation Sanatorium Techirghiol, Romania.

Nanopulsed electromagnetic field therapy is delivered using the Super Inductive System (SIS) device applied to the affected shoulder. The intervention is administered daily over a two-week period, with a total of 10 sessions. Each session lasts approximately 10-15 minutes. The therapy delivers high-intensity electromagnetic pulses with adjustable frequency and intensity, aiming to reduce pain, stimulate tissue regeneration, and improve functional outcomes.

Comparateur actif: Balneophysiotherapy Control Group

Participants allocated to the control group receive a structured two-week rehabilitation program comprising balneophysiotherapy interventions at the Balneal and Rehabilitation Sanatorium Techirghiol, Romania.

The intervention is based on the region's specific natural therapeutic resources and is conducted under continuous medical supervision. The treatment program includes saline therapeutic baths combined with exercise therapy and applications of sapropelic therapeutic mud, administered daily over a two-week period, five days per week. In addition, patients receive electrotherapy according to a standardized protocol, including magnetotherapy, interferential current therapy, and therapeutic ultrasound. The rehabilitation program also incorporates massage therapy and individualized therapeutic exercises.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Pain intensity assessed by Visual Analog Scale (VAS)
Délai: Baseline (T0), immediately after the 10-day treatment period (T1), 1 month after treatment completion (T2), and 3 months after treatment completion (T3).

Pain intensity will be measured using the Visual Analog Scale (VAS). Participants were asked to rate their current pain intensity by marking a point on a 100-mm horizontal line, where 0 indicates "no pain" and 100 indicates "worst pain imaginable." The score was recorded in millimeters (mm). Outcome range and interpretation: Minimum value: 0; Maximum value: 100. Higher scores indicate worse pain intensity.

Baseline (T0), immediately after the 10-day treatment period (T1), 1 month after treatment completion (T2), and 3 months after treatment completion (T3).

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Shoulder function assessed by Shoulder Pain and Disability Index (SPADI)
Délai: Baseline (T0), immediately after the 10-day treatment period (T1), 1 month after treatment completion (T2), and 3 months after treatment completion (T3).

Shoulder pain and disability were assessed using the Shoulder Pain and Disability Index (SPADI), a self-administered questionnaire consisting of two domains: pain (5 items) and disability (8 items). Each item is scored on a scale from 0 to 10, with higher scores indicating greater pain and functional impairment. The total SPADI score is expressed as a percentage (0-100%).

Baseline (T0), immediately after the 10-day treatment period (T1), 1 month after treatment completion (T2), and 3 months after treatment completion (T3).
Pressure Pain Threshold (PPT) assessed by digital algometry
Délai: Baseline (T0), immediately after the 10-day treatment period (T1), 1 month after treatment completion (T2), and 3 months after treatment completion (T3).

Pressure pain threshold will be measured using a digital algometer at standardized anatomical points of the shoulder. The mean value of repeated measurements will be recorded.

Baseline (T0), immediately after the 10-day treatment period (T1), 1 month after treatment completion (T2), and 3 months after treatment completion (T3).
Range of motion (ROM) assessed by goniometry
Délai: Baseline (T0), immediately after the 10-day treatment period (T1), 1 month after treatment completion (T2), and 3 months after treatment completion (T3).

Active range of motion of the shoulder (flexion, abduction, external rotation, internal rotation) will be measured using a goniometer.

Baseline (T0), immediately after the 10-day treatment period (T1), 1 month after treatment completion (T2), and 3 months after treatment completion (T3).
Muscle strength assessed by dynamometry
Délai: Baseline (T0), immediately after the 10-day treatment period (T1), 1 month after treatment completion (T2), and 3 months after treatment completion (T3).

Shoulder muscle strength was assessed using a handheld dynamometer. Measurements were performed for key shoulder movements, and values were recorded in kilograms. Higher values indicate greater muscle strength.

Baseline (T0), immediately after the 10-day treatment period (T1), 1 month after treatment completion (T2), and 3 months after treatment completion (T3).
Psychological status assessed by Hospital Anxiety and Depression Scale (HADS)
Délai: Baseline (T0), immediately after the 10-day treatment period (T1), 1 month after treatment completion (T2), and 3 months after treatment completion (T3).

Psychological status was assessed using the Hospital Anxiety and Depression Scale (HADS), which consists of 14 items divided into two subscales: anxiety (HADS-A) and depression (HADS-D), each containing 7 items. Participants rated how they had been feeling over the previous week. Each item is scored on a 4-point Likert scale ranging from 0 to 3. Subscale scores were calculated by summing the relevant item scores and are reported as unitless values. Outcome range and interpretation: HADS-A (Anxiety): Minimum value: 0; Maximum value: 21. Higher scores indicate greater anxiety severity. HADS-D (Depression): Minimum value: 0; Maximum value: 21. Higher scores indicate greater depressive symptom severity.

Baseline (T0), immediately after the 10-day treatment period (T1), 1 month after treatment completion (T2), and 3 months after treatment completion (T3).
Depression severity assessed by Patient Health Questionnaire-9 (PHQ-9)
Délai: Baseline (T0), immediately after the 10-day treatment period (T1), 1 month after treatment completion (T2), and 3 months after treatment completion (T3).

Depression severity will be assessed using the Patient Health Questionnaire-9 (PHQ-9), a self-administered questionnaire consisting of 9 items scored from 0 to 3. Total scores range from 0 to 27, with higher scores indicating greater severity of depressive symptoms.

Baseline (T0), immediately after the 10-day treatment period (T1), 1 month after treatment completion (T2), and 3 months after treatment completion (T3).
Quality of life assessed by EQ-5D-5L
Délai: Baseline (T0), immediately after the 10-day treatment period (T1), 1 month after treatment completion (T2), and 3 months after treatment completion (T3).

Quality of life was assessed using the EQ-5D-5L questionnaire, which evaluates five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels of severity. Higher scores indicate poorer quality of life.

Baseline (T0), immediately after the 10-day treatment period (T1), 1 month after treatment completion (T2), and 3 months after treatment completion (T3).

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Alexandra-Ecaterina Ciota, MD, Balneal and Rehabilitation Sanatorium Techirghiol

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

25 avril 2026

Achèvement primaire (Réel)

10 septembre 2026

Achèvement de l'étude (Réel)

10 septembre 2026

Dates d'inscription aux études

Première soumission

16 avril 2026

Première soumission répondant aux critères de contrôle qualité

20 avril 2026

Première publication (Réel)

24 avril 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner